Microwave-assisted synthesis of novel 2-naphthol *bis*-Mannich Bases

Po-Jung J. Huang,^a D. Youssef,^{a,b} T. Stanley Cameron,^c and Amitabh Jha^{a,*}

^a *Department of Chemistry, Acadia University, Wolfville, B4P 2R6, Nova Scotia, Canada*

^b *Département des Sciences, Université Sainte-Anne, Church Point, NS, B0W 1M0, Canada*

^c *Department of Chemistry, Dalhousie University, Halifax, B3H 4J3, Nova Scotia, Canada*

E-mail: amitabh.jha@acadiau.ca

Abstract

Mannich bases of 2-naphthol have the ability to chelate strongly to metal ions. Hence, they have great potential to be used as chiral catalysts, metallo-enzyme inhibitors and/or scavenger of heavy metal poisons. This paper deals with an efficient and expeditious microwave assisted-synthesis of novel bis-Mannich bases of 2-naphthols derived from aromatic aldehydes and diamines namely piperazine and *N,N'*-dialkylethylenediamines under solvent-free conditions. These compounds were also prepared under conventional reflux in ethanol. The compounds of this series displayed interesting NMR behaviour.

Keywords: 2-Naphthol bis-Mannich bases, microwave, 2-naphthol, Mannich reaction, NMR spectroscopy, X-ray crystallography

Introduction

Mannich bases find variety of commercial applications. It was estimated that at least 35% of Mannich bases related articles are published in pharmaceutical journals. They are known for their use in polymers, resins, surface active agents,¹ detergent additives,² and antioxidants.³ They have a broad range of biological activities including diuretic,⁴ antipsychotic,⁵ oxytocic,⁶ anticonvulsant,⁷ centrally acting muscle relaxant,⁸ antimalarial,^{9,10} antiviral¹¹ and anticancer.¹² Also, Mannich bases of various bioactive compounds have been prepared as prodrugs as a means of overcoming some of their limitations.¹²

Optically-pure chiral Mannich bases of 2-naphthol are particularly popular in metal-mediated and ligand-accelerated catalysis of enantioselective carbon-carbon bond formation.¹³⁻¹⁹ Many of these reactions involve the use of organozinc compounds as alkylating agents which are relatively unreactive if uncoordinated.¹³ These ligands may be used in catalytic amounts. The first synthesis of racemic Mannich-bases of 2-naphthol was achieved by Betti at the turn of the twentieth century.²⁰ Thereafter numerous modifications of this reaction surfaced.²¹⁻²⁷ Since these compounds have multiple centres for chelation with metal ions, they are likely to be potent

inhibitors of metallo-enzymes.²⁸⁻³¹ Also, these compounds have the potential to be used as scavengers in cases of heavy metal poisoning.^{32,33}

Hence, it is paramount to develop synthetic strategies around the naphthalene nucleus to gain easy access to variety of naphthalene derivatives. Previously, a novel and convenient procedure for the formation of Mannich bases of 2-naphthol under solvent free conditions was reported by our group.^{26,27} As part of the extension of this project, we herein report a microwave-assisted convenient and expeditious method for synthesizing *N,N'*-bis-[aryl-(2-hydroxynaphthalen-1-yl)-methyl]piperazines (**1**) and *N,N'*-bis(arylmethyl)-*N,N'*-bis(2-hydroxynaphthalen-1-yl-methyl)-ethylenediamines (**2**).

Results and Discussion

Reactions between 2-naphthol, aromatic aldehydes and piperazine resulted in the synthesis of *N,N'*-bis-[aryl-(2-hydroxynaphthalen-1-yl)-methyl]piperazines (Scheme 1). These reactions were studied under two conditions, as follows: A) Solvent-free microwave irradiation using CEM Discover S Class microwave oven at 125°C for five minutes in absence of any catalyst; B) Reflux in ethanol for 72 h in presence of catalytic amount of *p*TSA. Two *N,N'*-bis(arylmethyl)-ethylenediamines were also prepared utilizing non-cyclic secondary diamines in place of piperazine under microwave-assisted reactions (Scheme 2).

Scheme 1. Synthesis of *N,N'*-bis[aryl-(2-hydroxynaphthalen-1-yl)-methyl]-piperazines (**1a-l**). Conditions are depicted in Table 1.

Scheme 2. Synthesis of *N,N'*-bis(arylmethyl)-*N,N'*-bis(2-hydroxynaphthalen-1-yl-methyl)-ethylenediamines (**2a,b**).

Table 1. Physical data of *N,N'*-bis-[aryl-(2-hydroxynaphthalen-1-yl)-methyl]-piperazines (**1a-l**) and *N,N'*-bis(arylmethyl)-*N,N'*-bis(2-hydroxynaphthalen-1-yl-methyl)-ethylenediamines (**3a-b**)

Product	Ar	Reaction Method			
		Microwave [A]		Reflux [B]	
		M.p (°C)	% Yield	M.p (°C)	% Yield
1a		241-242	87	247-248	81, 60 ^a
1b		234-235	90	240-241	73
1c		243-244	84	243-244	51
1d		238-239	93	249-250	74
1e		248-250	81	254-255	50
1f		214-215	81	219-222	76
1g		225-226	40	243-245	65
1h		231-232	95	239-240	31
1i		229-230	56	237-238	65
1j		240-241	93	255-256	53
1k		215-216	92	219-220	51
1l		211-213	83	213-214	58
3a		152-154	71	-	-
3b		162-163	74	-	-

^aProduct yield from reaction without catalyst (*p*TSA).

All final compounds reported in this paper are new to the chemical literature and were completely characterized by spectroscopic means. To determine the actual spatial arrangement of atoms in the 3-D space, x-ray crystallography of compound **3b** was performed (Figure 1). The resolved structure shows the molecule in its most relaxed form with 2-naphthol and tolyl rings projecting in opposite directions. The H-bonding between phenolic H and N is clearly indicated at the two sites.

Figure 1. The ORTEP diagram of compound **3b** as obtained by X-ray crystallography.

The popularity of employing microwave energy in organic synthesis has tremendously increased in past decade owing to the simplicity, rapidity, high turnover and green nature of the reactions.³⁴⁻³⁶ Our previous endeavour which led to formation of simple Mannich bases of 2-naphthol under solvent-free conditions involved the use of a conventional kitchen microwave and *p*TSA as catalyst.^{26,27} As evident from data presented in Table 1, we were able to obtain *bis*-Mannich bases **1a-l** in good to excellent yields in absence of any catalyst using neat conditions under microwave irradiation; conventional reflux reactions in ethanol benefitted from the use of *p*TSA (Table 1, entry **1a**). The comparison of isolated yields, reaction time and material requirements of the two conditions employed showed microwave-assisted solvent-free reactions as the most efficient synthetic method in terms of energy and time consumption. It should be noted that none of the conditions herein presented were optimized, and the products obtained were not subjected to extensive purification. The products obtained through the reflux reaction protocol had the inherent advantage of digestion of insoluble product precipitates and therefore the purity of the obtained product were consistently better as evidenced by the sharper and higher melting point as compared to same products obtained by employing other conditions.

The final products in Scheme 1 (**1a-l**) contained two chiral centers meaning that three diastereomeric forms were possible. More specifically, the final product may include a pair of enantiomers and a *meso* stereoisomer. This was clearly observed in ^1H NMR spectra of a number of analogs where the H at the stereogenic centre appeared as two discrete peaks (Figure 3; spectra at 300 and 323K). In addition, we observed some difficulty with solubility for all compounds while trying to obtain NMR spectra. Interestingly, the isolated products were fairly soluble in CDCl_3 but precipitated after prolonged standing (~ 5 h). The precipitated compounds had poor solubility in CDCl_3 although the NMR spectra of dilute sample remained unchanged. This led us to speculate that the compounds were crystallizing in a new crystal lattice, exhibiting polymorphism. The precipitation of the compounds after prolonged standing also caused difficulty in recording ^{13}C NMR spectra where molecular dynamics²⁷ was already causing disappearance of some peaks at room temperature (*vide infra*); the problem was compounded by frequent appearance of two peaks for some of the carbons since the products were diastereomeric mixtures.

In ^1H -NMR, all compounds clearly showed strong hydrogen-bonding between phenolic H and neighboring N. However, peak broadening was causing ambiguity in the peak assignment. Both ^1H and ^{13}C NMR spectra of compounds suffered from peak broadening owing to molecular dynamics characteristic of cyclic amines.²⁷ To improve the resolution of the NMR spectra, variable temperature NMR experiments were conducted on compound **1b** (Figures 2-4). Recording of NMR spectra at lower temperature (253K) did improve the resolution but the peaks were still relatively broad.

Figure 2. Variable temperature ^1H -NMR stack plots of compound **1b**.

Figure 3. Variable temperature ^1H -NMR stack-plot of aliphatic region of **1b**.

Figure 4. Variable temperature ^{13}C -NMR stack-plot of aliphatic region of **1b**.

From the Figure 2, the H-bonds (12.8-13.6 ppm) were shown to be weakened by an increase in temperature. The protons and carbons on the piperazine ring displayed molecular dynamics presumably because of the possibility of restricted N-inversion at the two centers. The diastereotopic protons of piperazine appeared as broad peaks in the range 2.3-3.3 ppm at room temperature (~300 K) and above. These peaks were better resolved at lower temperatures (Figure 3). Interestingly with temperature increase, the 2 benzylic protons of enantiomeric pair and the *meso* diastereomer appeared to resolve better (5.0-5.2 ppm; Figure 3). The carbons on the piperazine ring did not display on ^{13}C NMR spectrum which was recorded at 300K or above (presumably because of peak broadening). At lower temperatures, not only did the ^{13}C NMR spectrum display the well resolved peaks, but also it showed discrete peaks in the range 50-55 ppm for each of the four carbons on the heterocyclic rings (Figure 4). This implied the magnetic non-equivalence of these carbons at experimental temperature due to distortion and loss of symmetry of the molecule.

In conclusion, fourteen *bis*-Mannich bases of 2-naphthol were successfully synthesized and purified. Although reflux conditions provided products with higher purity, the use of microwave-assisted conditions was shown to be the most efficient method of synthesizing compounds of this type in terms of atom economy, energy consumption and time required. Compounds displayed interesting molecular dynamic as evident by variable temperature NMR and peaks were found to be better resolved at sub-zero temperatures. These compounds may find use as catalysts or pharmaceuticals owing to their potential for metal chelation.

Experimental Section

General Procedures. All chemicals were obtained from Aldrich Chemical Co. Column chromatographic purifications were undertaken using silica gel (230-400 mesh) obtained from Silicycle. ^1H and ^{13}C NMR were recorded on Bruker AV500 and AV300 NMR spectrometers. ESI-HRMS spectra were obtained on Bruker microTOF instrument with an ESI source. Melting points were recorded on an electro-thermal apparatus and are uncorrected. UV-Vis and IR spectra were recorded on LKB Biochrom Ultraspec Plus 4054 and Nicolet Avatar 330 FT-IR spectrophotometers respectively. CEM Discover S-Class microwave reactor was used for the microwave-assisted reactions.

General synthesis of *N,N'*-Bis-[aryl-(2-hydroxynaphthalen-1-yl)-methyl]-piperazines (1a-l)
2-Naphthol (0.01mol), piperazine (0.005mol), and appropriate aromatic aldehydes (0.01mol) were combined and two reaction conditions were employed.

A. Solvent-free microwave irradiation using CEM Discover S Class microwave oven at 125°C for five minutes in absence of any catalyst.

B. In the reflux conditions, reaction mixtures in ethanol (40 ml) were refluxed for 72 hours. Catalytic amount of pTSA was added.

After the reaction proceeded for a stated period of time, respective of the reaction conditions, the insoluble products were sonicated in cold ethanol, filtered and air dried. Appearance, yield and melting points of products obtained under condition B are reported with experimental data.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-phenyl-methyl]piperazine (1a).** White powder; yield: 81%; m.p: 247-248 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.44-2.60 (m, 6H, 6x-NCH), 3.28 (bs, 2H, 2x-NCH), 5.15 (s, 2H, 2x-NCHAR₂), 7.12-7.27 (m, 5H, Ar-H), 7.39 (t, J=7.7Hz, 1H, Ar-H), 7.55 (d, J=7.5Hz, 2H, Ar-H), 7.69 (t, J=9.1Hz, 2H, Ar-H), 7.83 (d, J=8.6Hz, 2H, Ar-H), 13.20 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3416, 2120, 1635, 1270, 1119, 745 cm⁻¹. UV (EtOH, λ_{max}): 232, 282 nm. ESI HRMS (amu): measured for C₃₈H₃₄N₂O₂ [M+H]⁺ 551.2693; actual [M+H]⁺ 551.2699.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(4-toluy)l)-methyl]piperazine (1b).** White powder; yield: 73%; m.p: 240-241 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.24 (s, 6H, CH₃), 2.46-2.61 (m, 6H, 6x-NCH), 3.25 (s, 2H, 2x-NCH), 5.11 & 5.12 (s, 1H each, 2x-NCHAR₂), 7.04-7.24 (m, 12H, Ar-H), 7.35-7.45 (m, 4H, Ar-H), 7.64-7.82 (m, 4H, Ar-H), 13.20 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3418, 2099, 1636, 667 cm⁻¹. UV (EtOH, λ_{max}): 227, 280 nm. ESI HRMS (amu): measured for C₄₀H₃₈N₂O₂ [M+H]⁺ 579.3006; actual [M+H]⁺ 579.3012.

***N,N'*-Bis-[(4-fluorophenyl)-(2-hydroxynaphthalen-1-yl)-methyl]piperazine (1c).** Beige powder; yield: 51%; m.p: 243-244 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.32-2.60 (m, 6H, 6x-NCH), 3.28 (s, 2H, 2x-NCH), 5.14 & 5.15 (s, 1H each, 2x-NCHAR₂), 6.96 (t, J=8.4Hz, 4H, Ar-H), 7.11-7.16 (m, 2H, Ar-H), 7.24-7.29 (m, 2H, Ar-H), 7.38-7.43 (m, 2H, Ar-H), 7.50-7.55 (m, 2H, Ar-H), 7.67-7.79 (m, 8H, Ar-H), 13.10 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3414, 2099, 1634, 667 cm⁻¹. UV (EtOH, λ_{max}): 232, 280 nm. ESI HRMS (amu): measured for C₃₈H₃₂F₂N₂O₂ [M+H]⁺ 587.2505; actual [M+H]⁺ 587.2510.

***N,N'*-Bis-[(4-chlorophenyl)-(2-hydroxynaphthalen-1-yl)-methyl]piperazine (1d).** White powder; yield: 74%; m.p: 249-250 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.29-2.61 (m, 6H, 6x-NCH), 3.27 (s, 2H, 2x-NCH), 5.13 & 5.14 (s, 1H each, 2x-NCHAR₂), 7.11-7.15 (m, 2H, Ar-H), 7.24 (d, J=8.1Hz, 2H, Ar-H), 7.41 (t, J=7.5Hz, 2H, Ar-H), 7.49 (d, J=8.4Hz, 4H, Ar-H), 7.67-7.86 (m, 8H, Ar-H), 12.90 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3422, 2108, 1634, 1409, 1225, 947 cm⁻¹. UV (EtOH, λ_{max}): 227 nm. ESI HRMS (amu): measured for C₃₈H₃₂Cl₂N₂O₂ [M+H]⁺ 619.1914; actual [M+H]⁺ 619.1919.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(4-methoxyphenyl)-methyl]piperazine (1e).** Yellowish orange powder; yield: 50%; m.p: 254-255 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.29-2.61 (m, 6H, 6x-NCH), 3.25 (s, 2H, 2x-NCH), 3.72 (s, 6H, 2x-OCH₃), 5.10 (s, 2H, 2x-NCHAR₂), 6.78 (dd, J=8.7, 2.1 Hz, 4H, Ar-H), 7.11-7.14 (m, 2H, Ar-H), 7.20-7.28 (m, 2H, Ar-H), 7.35-7.46 (m, 6H, Ar-H), 7.65-7.72 (m, 2H, Ar-H), 7.80 (d, J=8.7Hz, 2H, Ar-H), 13.20 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3440, 2966, 2843, 2095, 1635, 1258, 1119, 947 cm⁻¹. UV (EtOH, λ_{max}): 229, 281 nm. ESI HRMS (amu): measured for C₄₀H₃₈N₂O₄ [M+H]⁺ 611.2904; actual [M+H]⁺ 611.2910.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(4-nitrophenyl)-methyl]piperazine (1f).** White powder; yield: 76%; m.p: 219-222 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.51-2.66 (m, 6H, 6x-NCH), 3.35 (s, 2H, 2x-NCH), 5.25 & 5.29 (s, 1H each, 2x-NCHAR₂), 7.11-7.16 (m, 2H, Ar-H),

7.43 (t, $J=7.2\text{Hz}$, 2H, Ar-H), 7.69-7.79 (m, 12H, Ar-H), 8.08-8.16 (m, 4H, Ar-H), 12.55 (bs, 2H, 2x-OH). IR (KBr; ν_{max}): 3413, 2908, 2381, 2108, 1635, 1521, 1115, 746 cm^{-1} . UV (EtOH, λ_{max}): 231, 270 nm. ESI HRMS (amu): measured for $\text{C}_{38}\text{H}_{32}\text{N}_4\text{O}_6$ $[\text{M}+\text{H}]^+$ 641.2395; actual $[\text{M}+\text{H}]^+$ 641.2400.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(4-(*N,N*-dimethylamino)phenyl)-methyl]piperazine (1g).** White powder; yield: 65%; m.p: 243-245 °C. ^1H NMR (300 MHz; CDCl_3): δ 2.18-2.240 (m, 6H, 6x-NCH), 2.65 (s, 12H, 4x-NCH₃), 2.99-3.23 (m, 2H, 2x-NCH), 5.05 (s, 2H, 2x-NCHAr₂), 6.58 (d, $J=8.1\text{Hz}$, 2H, Ar-H), 7.10-7.14 (d, $J=8.7\text{Hz}$, 2H, Ar-H), 7.22-7.25 (m, 2H, Ar-H), 7.35 (d, $J=7.8\text{Hz}$, 6H, Ar-H), 7.63-7.70 (m, 4H, Ar-H), 7.82 (d, $J=8.7\text{Hz}$, 2H, Ar-H), 13.31 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3425, 2115, 1639, 1520, 1454, 951, 814 cm^{-1} . UV (EtOH, λ_{max}): 232, 282 nm. ESI HRMS (amu): measured for $\text{C}_{42}\text{H}_{44}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 637.3539; actual $[\text{M}+\text{H}]^+$ 637.3543.

***N,N'*-Bis-[(3,4-dichlorophenyl)-(2-hydroxynaphthalen-1-yl)-methyl]piperazine (1h).** White powder; yield: 70%; m.p: 239-240 °C. ^1H NMR (300 MHz; CDCl_3): δ 2.42-2.78 (m, 6H, 6x-NCH), 3.29 (s, 2H, 2x-NCH), 5.11 & 5.12 (s, 1H each, 2x-NCHAr₂), 7.10-7.13 (m, 2H, Ar-H), 7.26-7.46 (m, 8H, Ar-H), 7.64-7.75 (m, 8H, Ar-H), 12.65 & 12.70 (bs, 1H each, 2x-OH). IR (KBr; ν_{max}): 3402, 2115, 1653, 668 cm^{-1} . UV (EtOH, λ_{max}): 230, 284 nm. ESI HRMS (amu): measured for $\text{C}_{38}\text{H}_{30}\text{Cl}_4\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 687.1134; actual $[\text{M}+\text{H}]^+$ 687.1140.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(3,4-dimethoxyphenyl)-methyl]piperazine (1i).** White powder; yield: 65%; m.p: 230-231 °C. ^1H NMR (300 MHz; CDCl_3): δ 2.50-2.61 (m, 6H, 6x-NCH), 3.15 (s, 2H, 2x-NCH), 3.79 (s, 12H, 4x-OCH₃), 5.09 (s, 2H, 2x-NCHAr₂), 6.75 (d, $J=8.4\text{Hz}$, 2H, Ar-H), 7.08-7.15 (m, 6H, Ar-H), 7.25-7.29 (m, 4H, Ar-H), 7.40 (t, $J=9.0\text{Hz}$, 2H, Ar-H), 7.66-7.73 (m, 4H, Ar-H), 7.83 (d, $J=8.7\text{Hz}$, 2H, Ar-H), 13.15 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3404, 2112, 1642, 1266, 939 cm^{-1} . UV (EtOH, λ_{max}): 232, 282 nm. ESI HRMS (amu): measured for $\text{C}_{42}\text{H}_{42}\text{N}_2\text{O}_6$ $[\text{M}+\text{H}]^+$ 671.3116; actual $[\text{M}+\text{H}]^+$ 671.3121.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(3,4-methylenedioxyphenyl)-methyl]piperazine (1j).** White powder; yield: 53%; m.p: 250-251 °C. ^1H NMR (300 MHz; CDCl_3): δ 2.41-2.66 (m, 6H, 6x-NCH), 3.24 (s, 2H, 2x-NCH), 5.07 & 5.09 (s, 1H each, 2x-NCHAr₂), 5.84 & 5.89 (s, 2H each, 2x-OCH₂O-), 6.70 (d, $J=8.1\text{Hz}$, 2H, Ar-H), 6.97-7.16 (m, 6H, Ar-H), 7.23-7.26 (m, 2H, Ar-H), 7.36-7.42 (m, 2H, Ar-H), 7.65-7.73 (m, 4H, Ar-H), 7.80 (d, $J=8.7\text{Hz}$, 2H, Ar-H), 13.09 & 13.10 (bs, 1H each, 2x-OH). IR (KBr; ν_{max}): 3557, 2109, 1634, 1241, 1029 cm^{-1} . UV (EtOH, λ_{max}): 229, 285 nm. ESI HRMS (amu): measured for $\text{C}_{40}\text{H}_{34}\text{N}_2\text{O}_6$ $[\text{M}+\text{H}]^+$ 639.2490; actual $[\text{M}+\text{H}]^+$ 639.2495.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(4-pyridyl)-methyl]piperazine (1k).** White powder; yield: %; m.p: 219-220 °C. ^1H NMR (300 MHz; CDCl_3): δ 2.45-2.79 (m, 6H, 6x-NCH), 3.31 (s, 2H, 2x-NCH), 5.48 (s, 2H, 2x-NCHAr₂), 7.10-7.14 (m, 4H, Ar-H), 7.25 (d, $J=9.0\text{Hz}$, 2H, Ar-H), 7.42 (t, $J=6.6\text{Hz}$, 2H, Ar-H), 7.56-7.72 (m, 8H, Ar-H), 8.05 (d, $J=9.0\text{Hz}$, 2H, Ar-H), 8.54 (d, $J=3.9\text{Hz}$, 2H, Ar-H), 12.85 (s, 2H, 2x-OH). IR (KBr; ν_{max}): 3385, 2113, 1634, 1466, 951 cm^{-1} . UV (EtOH, λ_{max}): 229 nm. ESI HRMS (amu): measured for $\text{C}_{36}\text{H}_{32}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$ 553.2598; actual $[\text{M}+\text{H}]^+$ 553.2604.

***N,N'*-Bis-[(2-hydroxynaphthalen-1-yl)-(2-pyridyl)-methyl]piperazine (1l).** Creamy yellow powder; yield: %; m.p: 210-212 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.45-2.79 (m, 6H, 6x-NCH), 3.31 (s, 2H, 2x-NCH), 5.15 & 5.16 (s, 1H each, 2x-NCHAr₂), 7.10-7.15 (m, 4H, Ar-H), 7.25 (d, J=9.0Hz, 2H, Ar-H), 7.44 (t, J=9.0Hz, 2H, Ar-H), 7.51 (d, J=5.7Hz, 4H, Ar-H), 7.68-7.80 (m, 6H, Ar-H), 8.52 (d, J=5.4Hz, 2H, Ar-H), 12.44 & 12.45 (bs, 1H each, 2x-OH). IR (KBr; ν_{max}): 3440, 2103, 1638, 1225, 943 cm⁻¹. UV (EtOH, λ_{max}): 227, 279 nm. ESI HRMS (amu): measured for C₃₆H₃₂N₄O₂ [M+H]⁺ 553.2598; actual [M+H]⁺ 553.2604.

Synthesis of *N,N'*-bis(arylmethyl)-*N,N'*-bis(2-hydroxynaphthalen-1-yl-methyl)-ethylene-diamines (3a,b)

Synthesis of *N,N'*-bis(arylethane)-1,2-diamine. Reported procedure³⁷ was followed for the synthesis of *N,N'*-bis(arylmethyl)-1,2-ethylenediamine. The diamine (1.00 mmol) and the corresponding aldehyde (2.00 mmol) were dissolved in methanol (10 mL) and stirred for 1 hour at room temperature and then cooled at 5 °C in an icebath. The precipitate (imine) was collected and washed extensively with cold methanol. The precipitate was then suspended in ethanol (100 ml) follow by addition of 0.67 molar equivalent of NaBH₄ portionwise. The reaction mixture was stirred at 55-60°C for 2 hour and then allowed to stand at room temperature for an hour. Solvent was rotary evaporated at this point and the crude product was extracted from EtOAc and water mixture. Dried EtOAc layer was rotary evaporated to dryness to produce the product **2**.

***N,N'*-Dibenzylethane-1,2-diamine (2a).** Yellow liquid. ¹H NMR (300 MHz; CDCl₃): δ 1.59 (s, 2H, NH), 2.82 (s, 4H, 2x-NCH₂), 3.82 (s, 4H, 2xArCH₂-), 7.15-7.30 (m, 10H, Ar-H).

***N,N'*-Bis(4-methylbenzyl)ethane-1,2-diamine (2b).** White powder; m.p. 112-114°C; lit m.p. 116°C.³⁸ ¹H NMR (300 MHz; CDCl₃): δ 1.59 (s, 2H, NH), 2.40 (s, 6H, 2x-ArCH₃), 2.81(s, 4H, 2x-NCH₂), 3.80(s, 4H, 2xArCH₂-), 7.19 (d, J=7.8Hz, 4H, Ar-H), 7.27(d, J=8.1 Hz, 4H, Ar-H).

Synthesis of *N,N'*-bis(arylmethyl)-*N,N'*-bis(2-hydroxynaphthalen-1-yl-methyl)-ethylene-diamines (3a,b)

2-Naphthol (1.88 g, 20 mmol), paraformaldehyde (600 mg, 20 mmol), and corresponding *N,N'*-bis(arylmethyl)-1,2-ethylenediamine (10 mmol) were mixed and reacted under solvent-free conventional microwave-assisted conditions at highest power (900 W) for 2 minutes. Precipitation occurred when ethanol (15 ml) was added. The products were sonicated in cold ethanol, filtered and air dried.

***N,N'*-Bis(2-hydroxynaphthalen-1-yl-methyl)-*N,N'*-bis(phenylmethyl)-ethylenediamine (3a).** White powder; yield: 71%; m.p: 152-154 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.87 (s, 4H, 2x-NCH₂CH₂N-), 3.62 (s, 4H, 2x-NCH₂Ph), 4.13 (s, 4H, 2x-NCH₂Naphthyl), 7.10 (d, J=8.7Hz, 4H, Ar-H), 7.18-7.33 (m, 2H, Ar-H), 7.41 (t, J=6.9Hz, 4H, Ar-H), 7.67-7.78 (m, 12H, Ar-H), 11.95 (s, 2H, 2x-OH). ¹³C NMR (75 MHz; 300 K; CDCl₃): δ 50.93, 53.42, 59.17, 111.69, 119.41, 121.32, 122.94, 126.81, 128.24, 129.08, 129.33, 129.81, 129.99, 129.99, 132.98, 136.34, 156.62. IR (KBr; ν_{max}): 3419. 2120, 1622, 814, 740 cm⁻¹. UV (EtOH, λ_{max}): 229, 277 nm. ESI HRMS (amu): measured for C₃₈H₃₆N₂O₂ [M+H]⁺ 553.2850; actual [M+H]⁺ 553.2855.

***N,N'*-Bis(2-hydroxynaphthalen-1-yl-methyl)-*N,N'*-bis(4-tolylmethyl)ethylenediamine (3b).** White powder; yield: 74%; m.p: 162-163 °C. ¹H NMR (300 MHz; CDCl₃): δ 2.31 (s, 6H, 2xArCH₃), 2.86 (s, 4H, -NCH₂CH₂N-), 3.58 (s, 4H, 2x-NCH₂Toluy), 4.11 (s, 4H, 2x-NCH₂Naphthyl), 7.07-7.11 (m, 4H, Ar-H), 7.28-7.32 (m, 4H, Ar-H), 7.30 (t, J=9.0Hz, 2H, Ar-H), 7.66-7.77 (m, 10H, Ar-H), 11.95 (s, 2H, 2x-OH). ¹³C NMR (75 MHz; 300 K; CDCl₃): δ 21.51, 50.83, 53.31, 58.71, 111.74, 119.44, 121.33, 122.89, 126.76, 128.98, 129.31, 129.31, 129.73, 129.97, 132.98, 133.18, 137.91, 156.68. IR (KBr; ν_{max}): 3409, 3051, 2132, 1623, 1266, 738 cm⁻¹. UV (EtOH, λ_{max}): 229, 276 nm. ESI HRMS (amu): measured for C₄₀H₄₀N₂O₂ [M+H]⁺ 581.3163. actual [M+H]⁺ 581.3168.

X-Ray crystallography. The purified compound (**3b**, 100 mg) as powder was dissolved in CHCl₃ (10 mL) and allowed to stand for 48 hours. The colourless crystals obtained were washed with cold acetonitrile and air dried. A colorless plate crystal having approximate dimensions of 0.32 x 0.26 x 0.18 mm was mounted on a glass fiber. All measurements were made on a Rigaku Mercury2 CCD area detector with graphite monochromated Mo-Kα radiation. Indexing was performed from 6 images that were exposed for 5.0 seconds. The crystal-to-detector distance was 50.10 mm. Cell constants and an orientation matrix for data collection corresponded to a C-centered monoclinic cell with dimensions: a=20.9975(8), b=9.3696(4), c=18.4218(7) Å, β=117.8154(11)°, V=3205.5(2) Å³. For Z=4 and FW=580.77, the calculated density is 1.203 g/cm³. Based on the systematic absences of hkl: h+k≠2n and h0l: l≠2n packing considerations, a statistical analysis of intensity distribution, and the successful solution and refinement of the structure, the space group was determined to be C2/c (#15).

The data were collected at a temperature of -50±1°C to a maximum 2θ value of 55.0°. Of the 16329 reflections that were collected, 3665 were unique (R_{int}=0.032); equivalent reflections were merged. Data were collected and processed using CrystalClear (Rigaku). The structure was solved by direct methods and expanded using Fourier techniques. The non-hydrogen atoms were refined anisotropically. Hydrogen atoms were refined using the riding model. The final cycle of full-matrix least-squares refinement on F was based on 2256 observed reflections (I>3.00σ(I)) and 220 variable parameters and converged (largest parameter shift was 0.00 times its esd) with unweighted and weighted agreement factors of R=0.0363 and R_w=0.0440. CCDC 700814 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Acknowledgements

We are grateful to Natural Sciences and Engineering Research Council (NSERC) for financial support. Ms C Nichols is thanked for preliminary investigations. The Atlantic Region Magnetic

Resonance Centre (ARMRC) and Maritime Mass Spectrometry Laboratory (MMSL) Dalhousie University are acknowledged for providing NMR and MS support, respectively.

References

1. Karll, R. E.; Lee, R. J. US Patent, US 4 384 138, 1983.
2. Otto, F. P. US Patent, US 3 649 229, 1972.
3. Horodysky, A. G.; Kaminski, J. M. US Patent, US 4 394 278, 1983.
4. Lee, L. M.; Plattner, J. J.; Ours, C. W.; Horrom, B. W.; Smital, J. R.; Martin, Y. C.; Pernet, A. G.; Bunnell, P. R.; El Masry, S. E.; Dodge, P. W. *J. Med. Chem.* **1984**, 27, 1579.
5. Scott, M. K.; Martin, G. E.; DiStefano, D. L.; Fedde, C. L.; Kukla, M. J.; Barrett, D. L.; Baldy, W. J.; Elgin R. J. Jr.; Kesslick, J. M.; Mathiasen, J. R.; Strank, R. P.; Vaught, J. L. *J. Med. Chem.* **1992**, 35, 552.
6. Cohen, A.; Hall, R. A.; Heath-Brown, B.; Parkes, M. W.; Rees, A. H. *British J. Pharmacol. Chemother.* **1957**, 12, 194.
7. Borenstein, M. R.; Doukas, P. H. *J. Pharm. Sci.* **1987**, 76, 300.
8. Shiozawa, A.; Narita, K.; Izumi, G.; Kurashige, S.; Sakitama, K.; Ishikawa, M. *Eur. J. Med. Chem.* **1995**, 30, 85.
9. Barlin, G. B.; Jiravinya, C. *Aus. J. Chem.* **1990**, 43, 1175.
10. Barlin, G. B.; Jiravinya, C.; Yan, J. H. *Aus. J. Chem.* **1991**, 44, 677.
11. Edwards, M. L.; Ritter, H. W.; Stemerick, D. M.; Stewart, K. T. *J. Med. Chem.* **1983**, 26, 431.
12. Dimmock, J. R.; Kumar, P. *Curr. Med. Chem.* **1997**, 4, 1.
13. Cardellicchio, C.; Ciccarella, G.; Naso, F.; Perna, F.; Tortorella, P. *Tetrahedron* **1999**, 55, 14685.
14. Cardellicchio, C.; Ciccarella, G.; Naso, F.; Schingaro, E.; Scordari, F. *Tetrahedron: Asymm.* **1998**, 9, 3667.
15. Palmieri, G. *Tetrahedron: Asymm.* **2003**, 11, 3361.
16. Liu, D. -X.; Zhang, L. C.; Wang, Q.; Da, C. S.; Xin, Z. Q.; Wang, R.; Choi, M. C. K.; Chan, A. S. C. *Org. Lett.* **2001**, 3, 2733.
17. Cimarelli, C.; Palmieri, G.; Volpini, E. *Tetrahedron: Asymm.* **2002**, 13, 2417.
18. Cimarelli, C.; Mazzanti, A.; Palmieri, G.; Volpini, E. *J. Org. Chem.* **2001**, 66, 4759.
19. Ji, J. X.; Qiu, L. Q.; Yip, C. W.; Chan, A. S. C. *J. Org. Chem.* **2002**, 68, 1589.
20. Betti, M. *Gazz. Chim. Ital.* **1900**, 30 II, 310.
21. Chi, K.-W.; Ahn, Y. S.; Shim, K. T.; Park, T. H.; Ahn, J. S. *Bull. Korean. Chem. Soc.* **1999**, 20, 973.
22. Saidi, M. R.; Azizi, N.; Naimi-Jamal, M. R. *Tetrahedron Lett.* **2001**, 42, 8111.
23. Saidi, M.; Khalaji, H. R. *J. Chem. Res. (Synop.)*, **1997**, 340.
24. Sharifi, A.; Mirzaei, M.; Naimi-Jamal, M. R. *Monatsh. Chem.* **2001**, 132, 875.

25. Katritzky, A. R.; Abdel-Fattah, A. A. A.; Tymoshenko, D. O.; Belyakov, S. A.; Ghiviriga, I.; Steel, P. J. *J. Org. Chem.* **1999**, *64*, 6071.
26. Paul, N.K.; Dietrich, L. M.; Jha, A. *Synth. Commun.* **2007**, *37*, 877.
27. Jha, A.; Paul, N. K.; Trikha, S.; Cameron, T. S. *Can. J. Chem.* **2006**, *84*, 843.
28. Brown, P. D. *Med. Oncol.* **1997**, *14*, 1.
29. Johnson, K. W.; Lofland, D.; Moser, H. E. *Curr. Drug Targets Infect. Disord.* **2005**, *5*, 39.
30. Lowther, W. T.; Matthews, B. W. *Biochim. Biophys. Acta.* **2000**, *1477*, 157.
31. Waller, A.S.; Clements, J. M. *Curr. Opin. Drug Discov. Devel.* **2002**, *5*, 785.
32. Chappell, L. T. *Altern. Med. Rev.* **1998**, *3*, 426.
33. Ford M.D. In *Heavy Metals*, 4th Ed.; McGraw Hill: New York, 1996.
34. Dallinger, D.; Kappe, C. O. *Chem. Rev.* **2007**, *107*, 2563.
35. Lidström, P.; Tierney, J.; Wathey, B.; Westman, J. *Tetrahedron* **2001**, *57*, 9225.
36. El Ashry, E. S. H.; Kassem, A. A. *Arkivoc* **2006**, (ix), 1.
37. Menage, S.; Baley, J. B.; Dumats, J.; Hussler, G.; Seite, M.; Luneau, I. G.; Chottard, G.; Fontecave, M. *J. Am. Chem. Soc.* **1998**, *120*, 13370.
38. Szabo, J. L.; Hill, D.; Bruce, W. F. US Patent, US 2 739 981, 1952.